...
首页> 外文期刊>The Southeast Asian journal of tropical medicine and public health >A comparative clinical trial of combinations of dihydroartemisinin plus azithromycin and dihydroartemisinin plus mefloquine for treatment of multidrug resistant falciparum malaria.
【24h】

A comparative clinical trial of combinations of dihydroartemisinin plus azithromycin and dihydroartemisinin plus mefloquine for treatment of multidrug resistant falciparum malaria.

机译:双氢青蒿素加阿奇霉素和双氢青蒿素加甲氟喹联合治疗对多药耐药的恶性疟疾的比较性临床试验。

获取原文
获取原文并翻译 | 示例
           

摘要

With the deteriorating situation of multidrug resistant falciparum malaria, a new drug or drugs in combinations are urgently needed. We conducted a study comparing a combination of dihydroartemisinin 240 mg and mefloquine 1,250 mg given over 3 days (Group 1) and a combination of dihydroartemisinin 240 mg and azithromycin 1,500 mg given over 3 days (Group 2), to determine safety, efficacy and tolerability. All of the patients stayed in a non-malaria endemic area during the study. By the third day after drug administration, most patients were free of parasites and none had serious adverse events. The cure rates at day 28 were 100% and 69.7% in Group 1 and Group 2, respectively (p<0.01). We conclude that a combination of dihydroartemisnin and azithromycin was safe and effective and may be another interesting regimen of the treatment of uncomplicated multidrug resistant Plasmodium falciparum malaria in Thailand.
机译:随着多药耐药性恶性疟疾的恶化,迫切需要一种新药或多种新药联合使用。我们进行了一项研究,比较了3天内给予的双氢青蒿素240 mg和甲氟喹1,250 mg的组合(第1组)和3天内给予的双氢青蒿素240 mg和阿奇霉素1,500 mg的组合(第2组),以确定安全性,有效性和耐受性。在研究期间,所有患者都住在非疟疾流行地区。给药后的第三天,大多数患者没有寄生虫,也没有严重的不良事件。第1组和第2组在第28天的治愈率分别为100%和69.7%(p <0.01)。我们得出的结论是,双氢青蒿素和阿奇霉素的组合是安全有效的,并且可能是在泰国治疗简单的多药耐药性恶性疟原虫疟疾的另一种有趣方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号